FEMY News and Press, Femasys Inc. From 12/23/21

ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company i...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...

Gainers: iSpecimen (NASDAQ:ISPC) +71%, Allied Healthcare Products (NASDAQ:AHPI) +68%, Adagio Therapeutics (NASDAQ:ADGI) +34%, Biofrontera (NASDAQ:BFRI) +31%, Moderna (NASDAQ:MRNA) +22%. Losers: Longeveron (NASDAQ:LGVN) -18%, IM Canna...

Shares of Femasys (NASDAQ:FEMY) hit a 52-week low today and closed down 20% on volume more than five times the normal average. Today, 204K shares traded hands. Average volume is 37,949. Femasys has two contraception productions both in phase 2 development: FemBloc for permanent both...

Gainers: Longeveron (NASDAQ:LGVN) +137%. Virtuoso (NASDAQ:VOSOU) +89%. Dicerna (NASDAQ:DRNA) +79%. ClearSign (NASDAQ:CLIR) +33%. Alpine (NASDAQ:ALPP) +22%. Macy's (NYSE:M) +21%. Enthusiast Gaming Holdings (NASDAQ:EGLX) +20%. BJ's (NYSE:BJ) +19%. Jowell Global (NASDAQ:JWEL) +17%. Yatsen Holdin...

Femasys (NASDAQ:FEMY): Q3 GAAP EPS of -$0.19. Cash and cash equivalents balance as of September 30, 2021 was $27.28M Press Release For further details see: Femasys reports Q3 results

-- Up to 792-patient, pivotal LOCAL trial progressing for FemaSeed ® after receipt of investigational device exemption (IDE) submission approval -- -- Femasys added to the Russell Microcap ® Index in Q3 -- ATLANTA, Nov. 10, 2021 (GLOBE NEW...

ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Se...

ATLANTA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologie...

-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform wome...